Transcript Why Should Physicians Test their Patients?

•
•
•
•
•
•
•
•
•
•
Fastest turn-around time - 3-5 business days
Developed the solution for processing PGX
Developed over 500 tests, incl early cancer
screening that detects some types of cancer
up to 6 months earlier than any other test
Far superior toxicology results (tests for 56 drugs)
Move urine specimens with blood immediately to
early cancer screen, so can be detected earlier
Revenue sharing program for qualified facilities
Easy to read reports
Advisors available for consultation daily
FREE SUPPLIES & SHIPPING
WALLET CARD for quick reference for any dr
Pharmacogenetics is the study of genetic
variations that influence individual response to
drugs. “It is the science that allows us to predict a
response to drugs, on an individual’s complete
genetic makeup.”
−Felix Frueh, Associate Director of Genomics, FDA
Helps prescribers individualize drug
therapy, decrease the chance for
adverse drug events, and increase the
effectiveness of drugs.
Availability of testing in your medical practice
with ease
•Non-invasive buccal swab.
•Covered by most insurance companies
•OB: refer to Black Box Warning of Codeine and other
analgesics
•PharmD reports are included with tests: equivalent to private,
individual Consult for each patient
discussing drug – gene, drug –drug interactions with
recommendations for alternatives.
•Financial Exposure to Patient: One-time, lifetime test for
patient vs other routine tests such as CBCs that over a lifetime
equal much more overall cost. Potential Rx savings on
unnecessary drugs when precise dosing is achieved first time
around.
•Weigh risk – benefit – one-time cost; peace of mind for
patient and physician; better patient satisfaction and
compliance, better outcome; less liability to physician.
Eliminate trial and error:
“Right Drug, Right Dose, Right Indication, Right Patient, Right Time”
Eliminate “One Size Fits All”medication management
Enhance Patient Care
Enhance Patient Satisfaction
Enhance Compliance
Risk Management: Reduce liability to physician
Manufacturers recommend pharmacogenetic testing prior to
or soon after initiation of therapy. FDA has also posted 16
drugs where it requires pharmacogenetic testing prior to
prescribing.
http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm0
83378.htm
Cleveland Clinic Journal of Medicine, Volume 78, Number 4, April 2011
• Inhibitor
– A substrate(drug) that slows down or “inhibits” the
metabolism of other substrates
• Inducer
– A substrate that increase the elimination of other
substrates
• Pro-drug
– A substrate that is biologically inactive in its
original (parent) form. These drugs must be
metabolized (“activated”)before they are work
in the body and produce their desired effect
Drug Metabolizing Phenotype
•Ultra Rapid Metabolizers (UM)
•Increased enzyme
•Extensive Metabolizers (EM)
•Normal
•Intermediate Metabolizers (IM)
•Impaired
•Poor Metabolizers (PM)
•Non functional
• SScenario #1- If a Physician group of 5 doctors performs 500 Paps/month
with
•
75 biopsies & 20 IHC @ $41 per biopsy and $60/IHC =
•
70 High Risk Pap Profile @ $200/case =
•
55 TERC FISH @ $140/case =
Testing
•DNA200
Urine Cytology @ $31/case =
•
200 Urine Feulgen Stain @ $14/case =
•
120 UroVysion FISH @ $56/case =
» Total Monthly PC Revenue
» Total Annual PC Revenue
$ 3,675
14,000
7,700
6,218
Custom
Compounds
2,800
6,720
$41,113
$493,356
» *Physician group must pay a local pathologist out of the PC
revenue
Partnership Examples
• Scenario #2- If a Physician group of 10 doctors performs 1,000 Paps/month
with
• 150 biopsies & 40 IHC @ $41 per biopsy and $60/IHC =
• 140 High Risk Pap Profile @ $200/case =
28,000
• 110 TERC FISH @ $140/case =
15,400
• 400 Urine Cytology @ $31/case =
$ 7,350
12,436
• 400 Urine Feulgen Stain @ $14/case =
5,600
• 240 UroVysion FISH @ $56/case =
13,440
Total Monthly PC Revenue
$82,226
Total Annual PC Revenue
$986,712
*Physician group must pay a local pathologist out of the PC revenue